{"id":1427,"date":"2024-08-26T06:42:17","date_gmt":"2024-08-26T06:42:17","guid":{"rendered":"https:\/\/swisspresse.com\/le-benefice-de-lentreprise-pharmaceutique-suisse-lonza-diminue-moins-que-prevu-et-les-actions-augmentent-25-07-2024-a-0919\/"},"modified":"2024-08-26T06:42:17","modified_gmt":"2024-08-26T06:42:17","slug":"le-benefice-de-lentreprise-pharmaceutique-suisse-lonza-diminue-moins-que-prevu-et-les-actions-augmentent-25-07-2024-a-0919","status":"publish","type":"post","link":"https:\/\/swisspresse.com\/fr\/le-benefice-de-lentreprise-pharmaceutique-suisse-lonza-diminue-moins-que-prevu-et-les-actions-augmentent-25-07-2024-a-0919\/","title":{"rendered":"Le b\u00e9n\u00e9fice de l&rsquo;entreprise pharmaceutique suisse Lonza diminue moins que pr\u00e9vu et les actions augmentent &#8211; 25\/07\/2024 \u00e0 09:19"},"content":{"rendered":"<p> <br \/>\n<\/p>\n<div id=\"\">\n<p>\n ((Traduction automatis\u00e9e par Reuters, veuillez consulter la clause<br \/>\nde non-responsabilit\u00e9 https:\/\/bit.ly\/rtrsauto))\n<\/p>\n<p>\n (R\u00e9\u00e9criture avec d\u00e9tails sur les actions, ajout d&rsquo;un<br \/>\ncommentaire d&rsquo;analyste, d\u00e9tails sur l&rsquo;unit\u00e9 Biologics, contexte;<br \/>\nparagraphes 1-4)<br \/>\npar Isabel Demetz et Andrey Sychev\n<\/p>\n<p>\n Le fabricant suisse de m\u00e9dicaments \u00e0<br \/>\nfa\u00e7on Lonza<br \/>\n <a href=\"https:\/\/www.boursorama.com\/cours\/2aLONN\/\"><br \/>\n  LONN.S<br \/>\n <\/a><br \/>\n a fait \u00e9tat jeudi d&rsquo;une baisse moins<br \/>\nimportante que pr\u00e9vu de son b\u00e9n\u00e9fice au premier semestre, la<br \/>\nbonne performance de son unit\u00e9 principale&#8230;<\/p>\n<\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/www.boursorama.com\/bourse\/actualites\/le-benefice-de-l-entreprise-pharmaceutique-suisse-lonza-diminue-moins-que-prevu-et-les-actions-augmentent-145a259fd77f9b75a0d0a09bb85dd968\">Source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>((Traduction automatis\u00e9e par Reuters, veuillez consulter la clause de non-responsabilit\u00e9 https:\/\/bit.ly\/rtrsauto)) (R\u00e9\u00e9criture avec d\u00e9tails sur les actions, ajout d&rsquo;un commentaire d&rsquo;analyste, d\u00e9tails sur l&rsquo;unit\u00e9 Biologics, contexte; paragraphes 1-4) par Isabel Demetz et Andrey Sychev Le fabricant suisse de m\u00e9dicaments \u00e0 fa\u00e7on Lonza LONN.S a fait \u00e9tat jeudi d&rsquo;une baisse moins importante que pr\u00e9vu de son [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[102],"tags":[],"class_list":{"0":"post-1427","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-business"},"_links":{"self":[{"href":"https:\/\/swisspresse.com\/fr\/wp-json\/wp\/v2\/posts\/1427","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/swisspresse.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/swisspresse.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/swisspresse.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/swisspresse.com\/fr\/wp-json\/wp\/v2\/comments?post=1427"}],"version-history":[{"count":0,"href":"https:\/\/swisspresse.com\/fr\/wp-json\/wp\/v2\/posts\/1427\/revisions"}],"wp:attachment":[{"href":"https:\/\/swisspresse.com\/fr\/wp-json\/wp\/v2\/media?parent=1427"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/swisspresse.com\/fr\/wp-json\/wp\/v2\/categories?post=1427"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/swisspresse.com\/fr\/wp-json\/wp\/v2\/tags?post=1427"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}